Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Media-OutReach Newswire Medical Taiwan 2025: Explore Cutting-Edge AI, Smart Medical Solutions, and Wellness Innovations